{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-010377","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2026-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.352065+00:00","generated_at":"2026-05-16T01:14:25.238222+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Foghorn Therapeutics appoints Ryan Maynard as CFO, replacing interim CFO Jeff Sacher","bullets":["Ryan Maynard appointed CFO effective February 23, 2026; succeeds Jeff Sacher (interim CFO).","Compensation: $510k base salary, 40% bonus target, $90k signing bonus, 400k share option grant.","Maynard brings 25+ years experience; most recently CFO of Cara Therapeutics (2022-2025).","Previously CFO at Rigel Pharmaceuticals, LetsGetChecked, and Blade Therapeutics; started career at Ernst & Young.","Maynard raised over $1B in financings and executed reverse merger for Cara with Tvardi Therapeutics."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-010377","json":"https://secwatch.observer/filing/0001628280-26-010377.json","markdown":"https://secwatch.observer/filing/0001628280-26-010377.md","text":"https://secwatch.observer/filing/0001628280-26-010377.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828026010377/0001628280-26-010377-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828026010377/fhtx-20260223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:14:25.238222+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}